Semaglutide attenuates myocardial ischemia-reperfusion injury by inhibiting ferroptosis of cardiomyocytes via activation of PKC-S100A9 axis
Semaglutide can reduce I/R-induced myocardial injury by inhibiting the ferroptosis of cardiomyocytes. In the mechanism, semaglutide mainly reduce the expression of S100A9 via the activation of PKC signaling pathway. Therefore, semaglutide is considered as a potential treatment option for MIRI.
Authors
- Xiaomeng Xu (ORCID: https://orcid.org/0000-0003-3695-4845)
- Bing Han (ORCID: https://orcid.org/0009-0000-5517-4372)
- Wenwu Zhu (ORCID: https://orcid.org/0000-0003-2236-9290)
- Yan Liu (ORCID: https://orcid.org/0000-0002-3961-9172)
- Miaomiao Zhang (ORCID: https://orcid.org/0000-0002-3577-6170)
- Zixuan Li (ORCID: https://orcid.org/0009-0000-9617-3982)
- Yingyu Chen (ORCID: https://orcid.org/0000-0002-1559-5698)
- Yan Zou (ORCID: https://orcid.org/0000-0001-9740-317X)
Institutions
- Xuzhou Medical College (CN)
- Xuzhou Central Hospital (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-03-20
- DOI
- https://doi.org/10.3389/fphar.2025.1529652
- Citations
- 7
- Primary Topic
- S100 Proteins and Annexins
- Type
- article
- Field-Weighted Citation Impact
- 5.64